--- title: "Intuitive Surgical to pay $450 million to settle hospitals' antitrust suit; revenue per procedure falls 3-5%" description: "Intuitive settled the hospitals' instrument-servicing antitrust case for $450 million, then disclosed its own 3-5% per-procedure price cut for 2027. The recurring revenue that carries 84% of sales now faces cheaper instruments on two fronts, just as US procedure growth slows to 10%." publisher: "The Inference" section: "Health" published: 2026-10-23T16:20:26.101Z modified: 2026-10-23T16:20:26.101Z canonical: https://theinference.org/article/intuitive-surgical-to-pay-450-million-to-settle-hospitals-antitrust-suit-revenue-per-procedure-falls-3-5 language: en keywords: "Intuitive Surgical, Antitrust, Medical Devices, Surgical Robots, Earnings" --- # Intuitive Surgical to pay $450 million to settle hospitals' antitrust suit; revenue per procedure falls 3-5% > Intuitive settled the hospitals' instrument-servicing antitrust case for $450 million, then disclosed its own 3-5% per-procedure price cut for 2027. The recurring revenue that carries 84% of sales now faces cheaper instruments on two fronts, just as US procedure growth slows to 10%. [Intuitive Surgical](https://theinference.org/markets/companies/intuitive-surgical) agreed on Monday to pay $450 million to settle [the hospitals' antitrust case over da Vinci instrument servicing](https://theinference.org/article/intuitive-surgical-settles-hospitals-da-vinci-antitrust-case-for-450-million-the-conduct-terms-are-unread), and the next evening its Q3 print conceded the pricing point anyway: from the first half of 2027, its own [Extended Use Program 2.0 plus China's regulated price cuts](https://theinference.org/article/intuitive-surgical-cuts-da-vinci-revenue-per-procedure-3-to-5-stock-falls-8-to-405-despite-a-beat) will lower instrument-and-accessory revenue per procedure by 3% to 5% [4][1][3]. Those plaintiffs are the company's own hospital customers, who alleged that contract terms blocked third-party servicing of the instruments. The lede's point stands on its own: nearly all of Intuitive's profit comes from what hospitals buy after they own the robot. Recurring revenue, mostly instruments, accessories and service, was 84% of the quarter's $3.05 billion in sales, which rose 22% year over year, and it carries a 69.9% non-GAAP gross margin [4][1][3]. That is the profit core management just deliberately trimmed. *Chart: **Recurring revenue, mostly instruments and service, is $2.3B of $3.05B** Column chart of Intuitive Surgical Q3 2026 revenue split: instruments and accessories $1,797 million, systems $769 million, service $482 million, from the 10-Q.* *Intuitive Surgical revenue by type, Q3 2026, US$ millions, from the Form 10-Q filed October 21, 2026. Instruments and accessories plus service make up the recurring stream the company reported at 84% of sales. [4]* ## The settlement leaves the conduct terms unread [The 10-Q shows the company and plaintiffs reached a written agreement after an October mediation](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm), without any admission of liability, but it still needs court approval and the filing names no conduct terms [4]. A court had already found, then vacated on market definition, [rulings that the EndoWrist instrument repair market is a monopoly aftermarket](https://theinference.org/article/three-fronts-one-earnings-date-intuitive-s-robot-monopoly-gets-tested); what carries forward is that a trial date had been set for September 14, 2027, the same year the price cuts land [4]. What the settlement actually lets third-party servicers do is unread, and that document could cheapen the blades further. ## The quarter was strong, but US volume slowed Adjusted EPS of $3.00 beat consensus near $2.65 [1]. The company placed 546 systems, 315 of them the newer da Vinci 5 [2], and international procedures grew 20%, with benign surgery like hernia repair up 41% abroad [1][3]. But US procedure growth slowed to 10%, the lowest rate since the early pandemic era, and 2026 guidance narrowed to 14-15% [1][3]. *Chart: **US procedure growth ran 10% in Q3, half the international rate; benign work abroad grew 41%** Column chart comparing Q3 2026 year-over-year procedure growth: 10% in the US, 20% internationally and 41% for international benign procedures such as hernia repair.* *Year-over-year procedure growth by segment, Q3 2026, percent. Benign procedures cover work such as hernia repair. Sources: AInvest and the Yahoo Finance (Moby) Q3 2026 earnings call summary. [1][3]* The bet is elasticity: cheaper instruments pull in ambulatory surgery centers and high-volume benign work fast enough to replace the price. If volumes do not answer, 2027 delivers falling revenue per procedure on slowing US growth while the court rules on the deal [4][2]. The $1.49 GAAP EPS, down from $1.95 after the after-tax $347 million settlement hit, is the least of it [4][2]. ## The stock swung, and the question is the multiple The market has not resolved this: [shares fell 7.31% after hours, then rose 3.67% the next day on $1.22 billion of volume](https://www.ainvest.com/news/intuitive-surgical-tops-trading-volume-earnings-beat-litigation-pricing-fears-2610/), the heaviest of the session [1]. The investor question is whether a premium multiple survives a deliberate concession at the profit core, contested by its own customers and by China's regulators, before the conduct terms are even public. Watch the 2027 volume response, not the settlement headline. ## Takeaway Intuitive Surgical agreed to pay $450 million to settle the hospitals' instrument-servicing antitrust case, then disclosed that its own price cuts plus China's will lower instrument revenue per procedure 3% to 5% from 2027. With recurring revenue at 84% of sales and US procedure growth at 10%, the bet is that cheaper instruments pull in enough volume to replace the price. ## Sources 1. [AInvest, Intuitive Surgical Tops Trading Volume as Earnings Beat Litigation and Pricing Fears, 23 October 2026](https://www.ainvest.com/news/intuitive-surgical-tops-trading-volume-earnings-beat-litigation-pricing-fears-2610/) 2. [TradingView (GuruFocus), Intuitive Surgical Drops as $450 Million Charge Overshadows Beat, 22 October 2026](https://www.tradingview.com/news/gurufocus:2e4516fde094b:0-intuitive-surgical-drops-as-450-million-charge-overshadows-beat/) 3. [Yahoo Finance (Moby), Intuitive Surgical, Inc. Q3 2026 Earnings Call Summary, 21 October 2026](https://finance.yahoo.com/healthcare/articles/intuitive-surgical-inc-q3-2026-123000899.html) 4. [SEC EDGAR, Intuitive Surgical Form 10-Q for quarter ended 30 September 2026, filed 21 October 2026](https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm) --- Intuitive Surgical to pay $450 million to settle hospitals' antitrust suit; revenue per procedure falls 3-5% — The Inference. Canonical: https://theinference.org/article/intuitive-surgical-to-pay-450-million-to-settle-hospitals-antitrust-suit-revenue-per-procedure-falls-3-5